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(QIV), comparing to TIV, in age-stratified populations of Hong Kong from 2001-2010 
years. Methods: TIV-unmatched influenza B infection rates with QIV versus TIV 
were estimated by an epidemiology model. Model parameters included percentages 
of influenza B lineages in circulation, influenza B-associated hospital admission, 
age-specific population, vaccine coverage and effectiveness. Events (outpatient 
care, hospitalizations and death) caused by infection of the influenza B lineage 
not included in TIV coverage in each year were calculated. Cost savings and QALYs 
gained from reduced events with QIV were estimated. Incremental cost per QALY 
gained (ICER) by QIV versus TIV were estimated from Hong Kong’s societal perspec-
tive. Results: All-age mean reduction in influenza B infection rate (per 100,000) 
was 25.9 (95%CI 6.7-45.1). Highest age-specific rate reduction was 451.4 (95%CI 87.7-
815.1) in ≥ 80 years, followed by 104.8 (95%CI 27.2-182.4) in 65-79 years and 13.2 
(95%CI 7.0-19.4) in 6 months-4 years. Highest cost savings and QALY gain occurred 
in years with high percentage (81.8%-96.4%) of circulated influenza B lineage not 
covered by TIV. QIV was more cost-effective than TIV in 6 years when it cost USD1 
more than TIV. When QIV was USD2, USD5 and USD10 more costly, it became cost-
effective in 3, 3 and zero years, respectively. ConClusions: QIV was cost-effective 
in very young and older populations. Cost-effectiveness of QIV was subjected to unit 
cost of QIV versus TIV and percentage of circulating influenza B lineages.
PIN83
XPert Mtb/rIf AssAy for rAPId dIAgNosIs IN PAtIeNts wIth susPected 
tuberculosIs IN hoNg KoNg - A cost-effectIveNess ANAlysIs
You J., Lui G., Kam K.M., Lee N.
The Chinese University of Hong Kong, Shatin, Hong Kong
objeCtives: Hong Kong is a developed city with intermediate tuberculosis (TB) 
burden of 90 per 100,000 population and low HIV prevalence. The diagnosis of TB 
in hospitalized patients was difficult due to atypical manifestation and low sen-
sitivity of sputum acid-fast bacilli (AFB) smear microscopy examination. Failure to 
receive early anti-TB treatment during initial assessment was identified to be an 
independent predictor associated with increased risk of mortality. We examined the 
cost-effectiveness of rapid diagnosis with Xpert MTB/RIF in patients hospitalized for 
suspected active pulmonary tuberculosis (PTB) from the perspective of Hong Kong 
public health care providers. Methods: A decision tree was designed to simulate 
outcomes of three diagnostic assessment strategies in adult patients hospitalized 
for suspected active PTB: conventional approach, sputum smear plus Xpert for AFB 
smear-negative, and a single sputum Xpert test. Model inputs were derived from 
literature. Outcome measures included direct medical cost, one-year mortality rate, 
quality-adjusted life-years (QALYs) and incremental cost per QALY (ICER). Results: 
In base-case analysis, one-year mortality rate of the Xpert group was 9.0% with 8.289 
QALYs gained. Comparing to smear plus Xpert, the Xpert group was more effective by 
an ICER of USD99. Conventional approach was the least preferred option with highest 
cost, lowest QALYs gained and highest mortality rate. Sensitivity analysis showed that 
Xpert would be the most cost-effective option if the sensitivity of sputum AFB smear 
microscopy was 74% or less. In 10,000 Monte Carlo simulations, the probabilities of 
Xpert, smear plus Xpert and conventional approach to be cost-effective were 94.5%, 
5.5% and 0%, respectively. ConClusions: Xpert sputum test appears to be a highly 
cost-effective diagnostic strategy for patients with suspected active PTB in intermedi-
ate burden area like Hong Kong.
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objeCtives: To estimate the cost effectiveness ratio of a inactivated quadrivalent 
influenza vaccine compared to the trivalent ones in France. Methods: During 
some epidemic influenza seasons a mismatch between the circulating B strains 
and the one included in the trivalent vaccine is observed. The difference of vaccine 
protection by the quadrivalent vaccine due to the inclusion of both circulating B 
strains should avoid the occurrence of a number of consultations and complications 
resulting in hospitalizations and deaths. A decision tree model was built to compare 
the efficacy and costs of the two vaccines for an average epidemic influenza season 
in the French setting. The number of hospitalization and deaths associated with 
influenza were estimated from an analysis of available French data. Estimates of 
these medical events were calculated using French standard costs in 2012 and obser-
vational data. Deterministic and probabilistic sensitivity analyses (PSA) were con-
ducted. Results: The base case analysis considered the global French vaccinated 
population during an average epidemic season between seasons 03/04 and 11/12 
with a B circulating virus rate of 23% and a mismatch rate of 58%. The perspective is 
collective. The number of avoided consultations for influenza was estimated at 6,214 
and the number of avoided hospitalizations and deaths at 614 and 372 respectively. 
The number of life years gained (LYG) was estimated at 5,382. The cost per LYG was 
estimated at 3,138€ /LYG. Sensitivity analyses showed clearly the importance of the 
B circulating virus rate combined with the mismatch rate highly variable according 
to influenza seasons. PSA showed that 100% of estimates in the acceptability curve 
were under 20,000€ per LYG in the base case analysis. ConClusions: The cost 
effectiveness ratio of an inactivated quadrivalent influenza vaccine compared to 
trivalent ones in the French setting can be considered acceptable.
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per patient QALYs was 0.849 and 0.841 respectively. Viremia remained undetectable 
and CD4 stable in all patients. Additionally, other parameters such as Cholesterol, 
HDL and Triglycerides levels improved when switching from STR-containing EFV to 
Rilpivirine-based STR. VAS analysis of health status perception also increased over-
all from 82.78 to 83.79 (scale: 0-100) due to the improvement in the STR-containing 
RPV arm. STR with RPV dominated (i.e. was more effective and less costly) EFV STR 
regimen, as measured by outcomes. ConClusions: Switching from STR containing 
Efavirenz to STR containing Rilpivirine is a safe, well tolerated strategy that improves 
the overall health status of HIV–treated patients. The switch does not expose patients 
to a risk of virologic failure due to possible PK interactions of the drugs. RPV compared 
to EFV resulted cost-effective showing lower cost and higher outcome measure values.
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objeCtives: HIV is a life-threatening disease in terms of a major global public health 
problem. This analysis evaluates the cost-effectiveness comparison of HIV-1 treatment 
alternatives including lamivudine+zidovudine+efavirenz (3TC/AZT+EFV), tenofovir 
DF+emtricitabine+efavirenz (FTC/TDF+EFV), tenofovir DF+emtricitabine+ritonavir+ 
lopinavir (FTC/TDF+LPV/r), tenofovir DF+emtricitabine+ darunavir (FTC/TDF+ DRV+ 
r), and elvitegravir+cobicistat+emtricitabine+tenofovir DF (STRIBILD). Methods: This 
analysis compares the HIV treatment alternatives of 3TC/AZT+ EFV, FTC/TDF+EFV, FTC/
TDF+LPV/r, FTC/TDF+DRV+ r and STRIBILD. The adherence rates were calculated from 
the increase rate in CD4 cell count and the risk of hospitalization as the effectiveness 
values. The data were taken from patient files from Hacettepe University that consists 
of 252 patients and 12 year follow-ups with an outpatient clinic, interventions, labora-
tory and imaging tests, medication usage, side effects, comorbidity’s diseases and their 
treatments and complications. The costs of treatment of diseases were calculated by 
cost of disease methodology. Average annual cost per patient is calculated for health 
care technologies. Health technology effectiveness values are found from the literature 
review. Virological response success is used from clinical studies as an end-point for 
this analysis. The treatment cost comparison is calculated with the incremental cost 
effectiveness-ratio (ICER). Results: Results of the clinical effectiveness of the treat-
ment alternatives of 3TC/AZT+ EFV, FTC/TDF + EFV, FTC/TDF +LPV/r, FTC/TDF+ DRV+ 
r and STRIBILD were 58%, 75%, 78%, 84%, and 88%, respectively. In the cost -effective-
ness comparison analysis, the annual total treatment costs are calculated as 12531 
TL, 17524 TL, 24284 TL, 22987 TL, and 20868 TL, respectively. The total ICER analysis 
shows only STRIBILD, FTC/TDF+EFV and 3TC/AZT+EFV treatments are cost-effective, 
while the other treatment alternatives are not cost-effective. ConClusions: The HIV-1 
treatment study was conducted in Turkey on the cost-effectiveness of this treatment 
strategy. The clinical efficacy and the cost-effectiveness of STRIBILD shows that it is an 
effective treatment strategy for HIV patients.
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objeCtives: To perform comparative pharmacoeconomic analysis of ertapenem in 
patients with community-acquired complicated intraabdominal infection in com-
parison with alternative therapy moxifloxacin. Methods: Were reviewed research 
on the clinical effectiveness and safety of use of ertapenem to prevent postoperative 
inflammatory complications and lethal outcomes. Assess of the quality of research 
and level of evidence obtained in these results was performed. The results of the 
research PROMISE formed the basis of pharmacoeconomic model. The effectiveness 
of therapy in studies was assessed by the frequency of clinical and bacteriological 
success of treatment with the use of different modes of antibacterial therapy. We 
calculated the difference in direct medical costs for treatment by ertapenem and 
moxifloxacin and cost-effectiveness ratio. Results: According to a study J. J. De 
Waele et al., in patients treated with ertapenem, the frequency of clinical effect of 
treatment was higher than in the group of patients receiving moxifloxacin: 93,4% 
and 89.5%, respectively. The mortality rate associated with the development of 
severe sepsis, was also lower for ertapenem: 3,1% and 5.4% respectively. Direct 
medical costs accounted in the group of moxifloxacin with the average duration 
of therapy is 7 days was 1798 USD, in the group of ertapenem with the average 
duration of treatment 6.8 days - 1981 USD. When using moxifloxacin instead of 
ertapenem ICER for one additional prevented complication was 4688 USD, and for 
one surviving patient - 17027 USD. One way sensitivity analyses showed that the 
results of the model were not sensitive to changing the cost of ertapenem from 75% 
to 125 %. ConClusions: Pharmacoeconomic analysis showed that the application 
of ertapenem for the treatment of community-acquired complicated intra-abdom-
inal infections is expensive but more efficient and economically justified strategy.
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objeCtives: The seasonal trivalent influenza vaccine (TIV) covers two subtypes 
of influenza A (A/H1N1 and A/H3N2) plus one of the two influenza B lineages cir-
culating in humans. Co-circulation of both influenza B lineages (B/Victoria and 
B/Yamagata) was common in Hong Kong. We examined the difference in costs 
and quality-adjusted life-years (QALYs) gained by quadrivalent influenza vaccine 
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infection. ConClusions: Introducing QIV into the immunization program of the 
United States would prevent a substantial number of hospitalizations and deaths. 
Moreover, cost-effectiveness was shown to be favorable when a cost-effectiveness 
threshold of US$50,000 is applied.
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objeCtives: Approximately 483 patients in Slovakia are living with HIV, with 68 
new infections in 2013. Raltegravir (RAL) is reimbursed for HIV-1-infected treatment-
naive (TN) and treatment-experienced (TE) patients in Slovakia. The objective of this 
analysis was to determine the cost-effectiveness of dolutegravir (DTG) relative to 
RAL. Methods: This study is based on the Anti-Retroviral Analysis by Monte Carlo 
Individual Simulation model. A microsimulation approach simulates the outcome 
of anti-retroviral therapy by following virological suppression and CD4+ cell count 
throughout patients’ lifetime. Each treatment was assigned its specific efficacy, 
adverse events rates, and cardiovascular risk according to lipid parameters evolu-
tion; and costs and quality of life values were allocated by CD4+ cell count categories 
and attached to specific events. The analysis was performed from payer’s perspec-
tive in Slovak settings. Results: Over a lifetime, in TN patients the estimated total 
costs for the DTG strategy compared with the RAL were lower (220,731€ versus 
222,079€ ). The savings for DTG are mostly associated to the lower drug acquisition 
cost. The life expectancy was similar for the DTG and RAL (31.23 years and 30.82 
years). This translated into 0.057 QALYs. DTG was dominant treatment strategy in 
TN patients. In TE patients, the estimated total costs were slightly higher for the 
DTG strategy compared with the RAL (192,682€ versus 188,059€ ). These additional 
costs for the DTG are related to patients living longer with DTG over RAL (19.16 years 
versus 18.30 years). An increment of 0.275 QALYs for DTG was gained. The ICUR for 
the comparison of DTG and RAL was 16,805 € per QALY, which is below the threshold 
19,320€ defined as the limit at which an intervention would be considered as cost-
effective in Slovakia. ConClusions: At the proposed price and when compared to 
RAL, DTG is dominant in TN patients and cost-effective in TE patients.
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objeCtives: The aim of this exercise is to evaluate the cost-effectiveness of 
rotavirus vaccination when introduced amongst children as part of the National 
Immunization Program of Libya. Methods: We used a published simple decision 
tree model about rotavirus disease and the impact of vaccination. The model has 
been adapted to the Libyan situation for analyzing the cost-effectiveness of the 
vaccine among a birth cohort of 160,000 children followed over an at risk period of 
5 years. The evaluation of diarrhea events in 3 public hospitals helped to estimate 
the burden of rotavirus patients confirmed with lab testing during the period from 
August 2012 to April 2013. The economic analysis was done from 2 perspectives: 
health provider and patient. Uni-variate sensitivity analyses were conducted to 
assess the uncertainty in some of the variables in the model. Results: The evalu-
ation study of the 3 hospitals reported 545 diarrhea patients aged below 5 years 
old amongst whom 311 or 57% were rotavirus positive. The societal cost to treat a 
rotavirus diarrhea event was estimated at US$ 661/event. With the simple model we 
estimated that with a vaccine coverage rate of 98%, the vaccine may avoid 47,000 
rotavirus diarrhea events in the birth cohort over a period of 5 years. The estimated 
cost offset is around US$ 2 million. From a health care perspective including only 
direct medical cost the incremental cost-effectiveness ratio (ICER) with a vaccine 
price of US$ 27 per course was US$ 8,972 per QALY gained. This result is below 
the Libyan Gross Domestic Product (GDP) per capita of US$ 10,132. From a societal 
perspective the analysis shows cost savings of around US$ 16 per child in the birth 
cohort. ConClusions: The economic model shows that rotavirus vaccination 
could be an economically attractive intervention for Libya when compared with 
no vaccination.
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objeCtives: The presented economic model estimates costs and benefits of a 
new in vitro diagnostic kit for infective endocarditis (IE), developed by Hutman 
Diagnostics AG (Basel, Switzerland). The product applies molecular diagnos-
tics to detect bacteria in cardiac tissue. In order to assess the potential financial 
and economic performance of the novel kit as compared to standard micro-
biological cultures (MC), a health economic study for Switzerland has been con-
ducted. Methods: As the kit provides results within 4-6 hours after sampling 
instead of 2-3 days by MCs, three outcome scenarios for aetiopathology of IE were 
investigated by establishing a decision tree and potential economic savings were 
examined. The outcome spectra and their economic performance were assessed 
for both diagnostic methods. The first scenario includes decreased hospitalisation 
and earlier specific antibiotic treatment due to quicker diagnosis. The second sce-
nario focuses on the avoidance of reoperation, while the third scenario includes 
the mitigation of mortality. The quantitative model uses statistical data obtained 
from literature and interviews with clinical experts. Parameters quantified were e. g. 
capital and labour costs, costs for antibiotic treatment and productivity losses. 
objeCtives: To evaluate the cost-effectiveness of a new generation integrase 
inhibitor (INI), dolutegravir (DTG), in France, in treatment-experienced (TE) and 
INI-naïve HIV adults with at least two- classes resistance, compared to raltegravir 
(RAL), by adapting previously published Anti-Retroviral Analysis by Monte Carlo 
Individual Simulation (ARAMIS) model. Methods: ARAMIS is a microsimula-
tion model using 500,000 simulations with a lifetime analytic time horizon and a 
monthly cycle length. Markov health states were defined by HIV health state (with 
or without opportunistic infection). The initial cohort, efficacy and safety data 
of the model were derived from SAILING, a phase III pivotal study. Antiretroviral 
treatment (ART) algorithms were based on French guidelines (2013) and experts 
opinion according to patients’ treatment history, including INI resistance status. 
Costs were mainly derived from the study by Sloan et al. (2012), which included 
routine HIV and opportunistic infection care, and death. Results: The ARAMIS 
model indicates that DTG compared to RAL over a life time is associated with 
additional quality-adjusted life years (QALY; 10.751 versus 10.406, 0.345 difference) 
and additional costs (€ 391,273 versus € 385,568, € 5,705 difference). DTG increased 
costs are mainly related to a 9.1-month increase in life expectancy for DTG com-
pared with RAL, and consequently a longer time spent on ART. The incremental 
cost-effectiveness ratio (ICER) for DTG compared with RAL is € 16,526 per QALY and 
€ 15,341 per life year. About 83% and 14% of total lifetime costs were associated 
with ART and routine HIV care respectively. Univariate deterministic sensitiv-
ity analyses demonstrated the robustness of the model with ICER varying from 
€ 11,038 to € 48,197 per QALY. ConClusions: DTG is a cost-effective strategy in the 
management of TE patients in France considering a collective perspective. These 
results are mainly explained by the superior efficacy of DTG reported in SAILING 
and its higher genetic barrier to resistance relative to RAL.
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objeCtives: In 2012, NICE recommended protease inhibitors as first line treat-
ment for G1 HCV infection. The objective of the analysis was to assess the cost-
utility of SMV/PR versus recommended comparator regimens used to treat G1 and 
G4 patients in the NHS. Methods: The model involved a treatment phase fol-
lowed by a post-treatment Markov phase, capturing lifetime outcomes according 
to whether sustained virologic response (SVR) had been achieved. SMV/PR was 
compared with PR, telaprevir + PR (TVR/PR), and boceprevir + PR (BOC/PR) in G1 
treatment-naïve and treatment-experienced patients. In G4, SMV/PR was compared 
with PR. Dosage regimens, including response-guided therapy and futility stopping 
rules, were based on the EMA approved labels. G1 SVR estimates were derived from 
a mixed treatment comparison; a matching-adjusted indirect comparison was used 
for G4. Patient baseline characteristics were drawn from a UK HCV dataset analy-
sis and clinician opinion. Health state transition probabilities, utilities and health 
state costs were drawn from published UK analyses. Sensitivity analyses were con-
ducted to assess uncertainty around estimated costs and quality-adjusted life years 
(QALY). Results: The G1 model yielded an ICER for SMV/PR vs PR of £14,206/QALY 
for treatment-naïve and £9,793/QALY for treatment-experienced patients. SMV/PR 
dominated TVR/PR and BOC/PR in both patient groups. In G4, the ICER for SMV/PR 
vs PR was £20,791/QALY and £11,662/QALY for treatment-naïve patients using the 
two most appropriate studies for matching. The ICER was £12,070/QALY and £8,896/
QALY for treatment-experienced patients. In both models, multivariate probabilistic 
sensitivity analysis revealed that at a willingness to pay of £20,000/QALY, SMV/PR 
had the highest probability of being the most cost effective intervention, regardless 
of treatment experience. Results were robust to univariate and scenario sensitivity 
analyses. ConClusions: Compared to other regimens currently available within 
the NHS, SMV/PR is a cost-effective option to treat G1 and G4 HCV patients, regard-
less of treatment experience.
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bACKGRound: Currently used trivalent influenza vaccines (TIVs) contain two 
strains of influenza A and one strain of influenza B. However, co-circulation of two 
distinct B lineages and difficulties in predicting which lineage will predominate 
in the next season have led to frequent B-strain mismatches. Newly registered 
quadrivalent influenza vaccines (QIVs) include two B strains and might therefore 
provide wider protection. objeCtives: To evaluate the cost-effectiveness of using 
QIV versus TIV for routine influenza vaccination in the United States (US) during 
the next 20 years. Methods: A dynamic transmission model was used to estimate 
the additional protection offered by QIV over TIV against symptomatic influenza 
B disease. Subsequently, we used a decision tree model to determine the cost-
effectiveness of replacing TIV with QIV from a societal perspective. US data on 
influenza-related disease outcomes and corresponding costs were derived from 
published sources (e. g. Molinari et al. 2007). Results: Over 20 years, replacing TIV 
with QIV is predicted to prevent 13.3 million influenza B cases. According to our 
model this resulted in a reduction of 113,000 hospitalizations and 13,200 deaths. 
Moreover, 200,000 quality- adjusted life-years (QALYs), US$3.1 billion in medical 
costs and US$0.6 billion in indirect costs were saved. The base case estimate of 
the incremental cost-effectiveness ratio (ICER) was US$29,000 per QALY gained. 
Economic parameters with highest impact on the ICER were vaccine price, QALY 
loss due to influenza and probability of hospitalization or death given symptomatic 
